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Objectives. This study sought to compare the outcome of
percutaneous transluminal coronary angioplasty (PTCA) (n 5
834) and coronary artery bypass graft surgery (CABG) (n 5 1805)
in diabetic patients with multivessel coronary disease from an
observational database.
Background. There is concern about selection of revasculariza-
tion in diabetic patients with multivessel coronary artery disease.
Methods. Data were collected prospectively and entered into a
computerized database. Follow-up was by letter or telephone or
additional events resulting in readmission.
Results. After CABG there were more in-hospital deaths (0.36%
vs. 4.99%, p < 0.0001) and a trend toward more Q wave myocar-
dial infarctions than after PTCA. Five- and 10-year survival rates
were 78% and 45% after PTCA and 76% and 48% after CABG,
respectively (p 5 0.47). At 5 and 10 years, insulin-requiring
patients had lower survival rates of 72% and 31% after PTCA and
70% and 48% after CABG, respectively (p 5 0.54). Multivariate
correlates of long-term mortality were older age, low left ventric-
ular ejection fraction, heart failure and hypertension. In the total
group, insulin requirement was a correlate of long-term mortality.
For the total group, choice of therapy had a multivariate hazard
ratio close to 1. In the insulin-requiring subgroup, the multivar-
iate hazard ratio was 1.35 (95% confidence interval 1.01 to 1.79)
for PTCA versus CABG. Corrected for baseline differences, 5- and
10-year survival rates were 68% and 36% after PTCA and 75% and
47% after CABG, respectively, in the insulin-requiring subgroup.
Nonfatal events were more common after PTCA, especially addi-
tional revascularization.
Conclusions. This study reveals a high incidence of events in
diabetic patients and raises further questions about angioplasty
in insulin-requiring diabetic patients with multivessel disease.
(J Am Coll Cardiol 1998;31:10–9)
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Patients with diabetes mellitus have a marked propensity for
cardiovascular morbidity and mortality. Epidemiologic data
from the Framingham Study (1) demonstrated a twofold to
threefold increase in atherosclerotic disease in diabetic pa-
tients. The risk of death from cardiovascular causes is three
times higher for diabetic than nondiabetic men, even after
adjustment for age and presence of hypercholesterolemia,
hypertension and tobacco use (2). Similarly, the risk of myo-
cardial infarction, peripheral arterial disease and heart failure,
and the mortality associated with coronary ischemic events, are
increased significantly in diabetic patients (3).
Because of the prevalence of extensive atherosclerotic
disease, diabetic patients constitute an important segment of
the population undergoing coronary revascularization proce-
dures. Specifically, patients with diabetes mellitus account for
;20% of patients currently undergoing revascularization pro-
cedures (4–6). Revascularization of diabetic patients poses a
challenge because long-term event rates are known to be
higher than in nondiabetic patients (4,5,7). Furthermore, re-
cent data from the Bypass Angioplasty Revascularization
Investigation (BARI) (8) and the Coronary Angioplasty Ver-
sus Revascularization Investigation (CABRI) (9) have sug-
gested that diabetic patients treated with oral hypoglycemic
agents or insulin have a higher mortality with coronary angio-
plasty than with bypass surgery. There has been concern about
the ability to generalize these data from randomized trials to
other patient groups because the patients in the randomized
trials may not be entirely representative of broader patient
populations. Thus, it is necessary to examine observational
databases to place the randomized trial data in the proper
context.
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Methods
Patients. From January 1981 through December 1994,
2,639 diabetic patients with two- or three-vessel coronary
artery disease and no previous revascularization procedures
underwent either coronary angioplasty (n 5 834) or bypass
surgery (n 5 1,805) performed at Emory University Hospitals.
Included were patients undergoing procedures for stable or
unstable angina pectoris or after several days of stabilization
after acute myocardial infarction. Those who had the proce-
dure performed emergently in the setting of infarction were
excluded.
Definition of diabetes. The definition of diabetes follows
that of the American College of Cardiology (ACC) database.
Although patients were included in the present study before
the creation of the ACC database, the definition for the Emory
database has always been consistent with ACC database.
Patients were classified as having diabetes on the basis of
history, regardless of duration of disease or need for antidia-
betic agents. The diagnosis could be based on a previous
physician telling a patient that they had diabetes (in principle,
based on fasting, nonstressed blood sugar level .140 mg/dl on
at least two occasions, although this cannot reasonably be
verified) or taking or having previously taken oral hypoglyce-
mic agents or insulin or receiving diet therapy.
Other definitions. Single-vessel disease 5 $50% diameter
lumen narrowing in either the left anterior descending, left
circumflex or right coronary artery or a major branch or
branches; double-vessel disease 5 presence of .50% diameter
lumen narrowing in two of the three major epicardial vessel
systems; three-vessel disease 5 presence of .50% diameter
lumen narrowing in all three major epicardial vessel systems or
in the left anterior descending and proximal circumflex coro-
nary artery in left-dominant patients; left main coronary artery
disease 5 presence of .50% diameter lumen narrowing in the
left main coronary artery; urgent procedure 5 a procedure
judged by the operator to be required within 24 h; emergent
procedure 5 procedure performed in the setting of acute
ischemia or infarction; complete revascularization 5 all major
obstructions in the epicardial vessels are bypassed after bypass
surgery or successfully dilated by at least 20% and to ,50%
diameter stenosis after angioplasty; myocardial infarction 5
postprocedural myocardial infarction determined by the devel-
opment of new Q waves; variables defined by patient history 5
hypertension, severity of angina, previous myocardial infarc-
tion or myocardial infarction during follow-up. Angina was
defined by Canadian Cardiovascular Society Classification (10)
and congestive heart failure by New York Heart Association
criteria (11).
Angioplasty and bypass surgery procedures. All angio-
plasty procedures were performed using standard techniques
in use during the time that the procedure was performed and
have previously been described (12). Angioplasty procedures
included balloon dilation and stent implantation and the use of
other new devices. Because of the period during which most of
these patients were treated, the majority of the patients treated
with angioplasty underwent balloon angioplasty. For bypass
surgery, standard surgical techniques, extracorporeal circula-
tion and myocardial protection methods were used (13).
Data collection. Baseline and restudy demographic, clini-
cal, angiographic and procedural data, including complica-
tions, were recorded prospectively on standardized forms and
entered into a computerized data base. All fields are defined in
a data dictionary. Angiographic success was assessed by quan-
titative coronary arteriography performed by experienced an-
giographers involved in the procedure but other than the
primary operator.
Patient follow-up. Follow-up information was obtained
from the patients or their referring physicians. Follow-up
status for each end point was also assessed at each subsequent
hospital admission. Patients not readmitted were contacted by
telephone or letter. Follow-up data were available for 2,541
(96%) of the 2,639 patients. The mean length of follow-up was
5.0 6 3.6 years. Information obtained included occurrence of
myocardial infarction since the initial angioplasty, subsequent
need for an additional revascularization procedure (angio-
plasty or bypass surgery), death (cardiac plus noncardiac) and
recurrent angina. All follow-up information was recorded on
standardized forms and entered into the computerized data
base. All repeat procedures performed at Emory University
Hospitals were confirmed from the database. Myocardial in-
farctions during follow-up were ascertained largely from the
patients, and thus there may be both under and overreporting.
Statistical analyses. Results are expressed as proportions
or mean value 6 SD. Differences in categoric variables were
analyzed by chi-square analysis (or Fisher exact test), and
differences in continuous variables were analyzed by Student t
tests. The clinical, angiographic and procedural characteristics
of each group were determined. Overall survival (cardiac plus
noncardiac) and event-free survival were determined by the
Kaplan-Meier method (14), and the estimated probability is
shown together with the standard error of the estimate. Overall
survival and event-free survival analyses were performed for
the total population, as well as on the insulin-requiring sub-
group. End points analyzed included 1) survival; 2) freedom
from myocardial infarction; 3) freedom from additional
bypass surgery; 4) freedom from additional angioplasty; 5)
event-free survival, defined as freedom from the events of
death, myocardial infarction, additional bypass surgery or
additional angioplasty. Comparisons of total and event-free
survival were made using the Mantel-Cox method (15).
Multivariate correlates of survival were analyzed with Cox
model analysis (16) with repeated analyses with variables
Abbreviations and Acronyms
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BARI 5 Bypass Angioplasty Revascularization Investigation
CABRI 5 Coronary Angioplasty Versus Bypass Revascularization
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that were frequently missing eliminated to determine the
impact of missing data (and consequently fewer patients in
the model) on the analyses.
Results
Coronary angioplasty versus bypass surgery. The clinical
characteristics of all 834 patients treated with coronary angio-
plasty are compared with those of the 1,805 patients treated
with bypass surgery in Table 1. There was no difference in age,
with a mean age in the early 60s in both groups. More of the
angioplasty group patients were women. There was no differ-
ence in the incidence of hypertension. More of the angioplasty
group patients had severe angina, whereas more of the bypass
surgery group patients had heart failure and a previous myo-
cardial infarction. There was a large difference in vessels
diseased, with the majority of the angioplasty group patients
having two-vessel disease and the majority of the bypass
surgery group patients having three-vessel disease. Left ven-
tricular ejection fraction was in the low normal range and was
slightly higher in the angioplasty group patients. Emergent
procedures were unusual but were more common in the bypass
surgery group patients. In-hospital events and angina during
follow-up are shown in Table 2. Completeness of revascular-
ization was much higher with bypass surgery. Just over 3% of
the angioplasty group patients crossed over to bypass surgery
during the initial hospital period. There were more deaths and
a trend toward more Q wave myocardial infarctions in the
bypass surgery group. Recurrent angina was noted in just over
one third of each group at follow-up.
Coronary angioplasty versus bypass surgery in insulin-
requiring patients. The clinical characteristics of the 279
insulin-requiring patients treated with coronary angioplasty are
compared with those of the 610 insulin-requiring patients
treated with bypass surgery in Table 3. The patients are similar
to the total cohort. There was a trend to younger age in the
angioplasty group, with the mean age of both groups in the
early 60s. There was little difference in gender. There was no
difference in the incidence of hypertension. There was a trend
toward more of the angioplasty group patients having severe
angina, whereas more of the bypass surgery group patients had
heart failure. There was a large difference in vessels diseased,
with the majority of the angioplasty group patients having
two-vessel disease and the majority of the bypass surgery group
patients having three-vessel disease. Left ventricular ejection
fraction was in the low normal range and was slightly higher in





(n 5 1,805) p Value
Age 62 6 11 62 6 10 0.43
Women 297 (35.6%) 546 (30.2%) 0.007
Insulin
dependent
279 (33.9%) 610 (38.0%) 0.05
(n 5 823) (n 5 1,606)
Systemic HTN 538 (64.7%) 1,129 (63.6%) 0.63
CCS class III/IV
angina
618 (76.8%) 1,100 (69.3%) 0.0001
(n 5 805) (n 5 1,588)
CHF 72 (8.8%) 218 (13%) 0.002
(n 5 820) (n 5 1,676)
Previous MI 372 (45.6%) 951 (53.6%) 0.0002
2 VD 634 (76%) 676 (37.5%) , 0.0001
3 VD 200 (24%) 1,129 (62.5%) , 0.0001
LVEF 55 6 12 52 6 15 , 0.0001
(n 5 725) (n 5 1,676)
Elective 717 (94.1%) 1,627 (90.1%) 0.002
(n 5 762) (n 5 1805)
Urgent 40 (5.2%) 70 (3.9%) 0.14
(n 5 762) (n 5 1,805)
Emergent 5 (0.7%) 108 (6%) , 0.0001
(n 5 762) (n 5 1,805)
Data presented are mean value 6 SD or number (%) of patients. CCS 5
Canadian Cardiovascular Society; CHF 5 congestive heart failure; HTN 5
hypertension; LVEF 5 left ventricular ejection fraction; MI 5 myocardial
infarction; VD 5 vessel disease.






(n 5 1,805) p Value
Complete revascularization 137 (16.4%) 1,470 (81.4%) , 0.0001
Q wave MI 6 (0.72%) 27 (1.50%) 0.14
Bypass surgery 26 (3.12%) NA
In-hospital death 3 (0.36%) 90 (4.99%) , 0.0001
Angina during follow-up 271 (36.4%) 423 (34.5%) 0.41
Time to follow-up (yr) 3.7 6 2.7 5.7 6 3.7 , 0.0001
(n 5 744) (n 5 1,227)
Data presented are mean value 6 SD or number (%) of patients. MI 5
myocardial infarction; NA 5 not applicable.





(n 5 610) p Value
Age 60 6 12 62 6 11 0.07
Women 117 (41.9%) 234 (38.4%) 0.35
Systemic HTN 173 (62.2%) 374 (62.5%) 0.99
CCS class III/IV
angina
212 (77.9%) 396 (71.9%) 0.07
(n 5 272) (n 5 551)
CHF 26 (9.6%) 92 (16.4%) 0.01
(n 5 270) (n 5 561)
Previous MI 143 (52.2%) 333 (55.4%) 0.42
2 VD 206 (73.8%) 199 (32.6%) , 0.0001
3 VD 73 (26.2%) 411 (67.4%) , 0.0001
LVEF 53 6 12 50 6 15 0.003
(n 5 247) (n 5 559)
Elective 242 (91.7%) 542 (88.9%) 0.26
(n 5 264) (n 5 610)
Urgent 18 (6.8%) 19 (3.1%) 0.02
(n 5 264) (n 5 610)
Emergent 4 (1.5%) 49 (8.0%) 0.0004
(n 5 264) (n 5 610)
Data presented are mean value 6 SD or number (%) of patients. Abbrevi-
ations as in Table 1.
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the angioplasty group. Emergent procedures were unusual but
were more common in the bypass surgery group patients.
In-hospital events and angina during follow-up are shown in
Table 4. Completeness of revascularization was much higher
with bypass surgery. Just over 5.5% of the angioplasty group
patients crossed over to bypass surgery during the initial
hospital period. There were more deaths in the surgery group.
There was a slight trend toward more angina during follow-up
in the angioplasty group.
Survival. Survival for all diabetic patients is displayed in
Figure 1. Note that initially the surgical curve drops due to the
initial in-hospital mortality. Thereafter, the curves come to-
gether and largely overlap. The curves display continuing
mortality such that by 10 years, ,50% of patients are still alive.
Survival in the insulin-requiring subset is similar (Fig. 2), with
somewhat a lower survival than in the group overall, as shown
in the multivariate analysis that follows. The curves are again
seen to largely overlap. Multivariate correlates of long-term
mortality are shown in Figure 3, with the correlates for all
patients on top and for the insulin-requiring subgroup below.
Older age, low left ventricular ejection fraction, heart failure
and hypertension were correlates in the total population and in
the insulin-requiring subgroup, although with somewhat wider
confidence intervals in the latter. In the total group, insulin
requirement was a correlate of long-term mortality as well. For
the total group, the choice of therapy had a hazard ratio close
to 1, with the 95% confidence interval widely spanning 1. This
means that there is no evidence of a survival advantage of one
form of therapy over the other. For the insulin-requiring
subgroup, the results for the choice of therapy are less clear.
Although the survival curves overlapped, the bypass surgery
group patients were sicker. Thus, on multivariate analysis there
was higher mortality in the insulin-requiring subgroup for
coronary angioplasty than for bypass surgery (hazard ratio
[HR] 1.35, 95% confidence interval 1.01 to 1.79, p 5 0.045).
After correction for baseline differences, the 5- and 10-year
survival rates were 68% and 36% after coronary angioplasty
and 75% and 47% after bypass surgery, respectively, in the
insulin-requiring subgroup (Fig. 4). Of note, the number of
vessels diseased was not a multivariate correlate of mortality in
either the total group or the insulin-requiring subgroup. The
survival rate in the subgroup with two-vessel disease at 5 and
10 years was 76% and 51% for angioplasty and 78% and 49%
for bypass surgery, respectively (p 5 0.79).
Freedom from myocardial infarction. Freedom from myo-
cardial infarction for all patients is shown in Figure 5 and was
somewhat lower in the angioplasty group patients than in the
bypass surgery group patients. The results in the insulin-
requiring subset were essentially identical (data not shown).
The multivariate correlates of myocardial infarction were
Figure 1. Survival in all diabetic patients treated with
coronary bypass surgery or coronary angioplasty.






(n 5 610) p Value
Complete revascularization 44 (15.8%) 488 (80.0%) , 0.0001
Q wave MI 2 (0.72%) 6 (0.98%) 0.99
Bypass surgery 16 (5.73%) N/A
In-hospital death 0 33 (5.41%) 0.0002
Angina during follow-up 101 (42.9%) 139 (37.0%) 0.25
Time to follow-up (yr) 3.5 6 2.5 5.2 6 3.5 , 0.0001
(n 5 241) (n 5 376)
Data presented are mean value 6 SD or number (%) of patients. Abbrevi-
ations as in Table 2.
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coronary angioplasty as the choice of therapy (HR 1.85, p ,
0.0001) and younger age (HR 1.37/decade, p , 0.001).
Freedom from additional bypass surgery. Freedom from
additional bypass surgery for all patients is shown in Figure 6.
There is considerably lower freedom from additional bypass
surgery in the angioplasty group. The highest incidence of
bypass surgery in the angioplasty group is in the initial 6
months to 1 year, during the period of maximal restenosis. In
contrast, in the bypass surgery group, the incidence is initially
low but then increases over time, consistent with graft failure
or progression of disease. The results in the insulin-requiring
subgroup were similar (data not shown). The results were also
similar in the subgroup with two-vessel disease, with 5- and
10-year freedom from bypass surgery of 75% and 50% in the
angioplasty group and 97% and 82% in the bypass surgery
group, respectively. The multivariate correlates of additional
bypass surgery were angioplasty as the choice of therapy (HR
8.4, p , 0.0001) and younger age (HR 1.36/decade, p ,
0.0001).
Incidence of additional angioplasty. The incidence of ad-
ditional angioplasty for all patients is shown in Figure 7. There
was a considerably higher incidence in the angioplasty group,
with the highest rate in the first 6 months. The incidence in the
bypass surgery group gradually increased over time. The
results in the insulin-requiring subgroup were similar (data not
shown). The results were also similar in the subgroup with
two-vessel disease, with 5- and 10-year freedom from coronary
angioplasty of 58% and 46% in the angioplasty group and 93%
Figure 2. Survival in insulin-requiring diabetic patients
treated with coronary bypass surgery or coronary angio-
plasty.
Figure 3. Multivariate correlates of long-survival term
for all diabetic patients (top) and for insulin-requiring
patients (bottom) treated with coronary bypass surgery
or coronary angioplasty. Short vertical lines 5 hazard
ratio for each correlate; horizontal lines 5 95% confi-
dence intervals. CABG 5 coronary artery bypass graft
surgery; EF 5 left ventricular ejection fraction;
PTCA 5 percutaneous transluminal coronary angio-
plasty.
14 WEINTRAUB ET AL. JACC Vol. 31, No. 1
PTCA VERSUS CABG IN DIABETIC PATIENTS January 1998:10–9
and 79% in the bypass surgery group, respectively. The multi-
variate correlates of additional coronary angioplasty were
angioplasty as the choice of therapy (HR 7.4, p , 0.0001),
higher left ventricular ejection fraction (HR 1.13/10% in-
crease, p 5 0.0024) and more severe angina at baseline (HR
1.13/one-point increase in angina class, p 5 0.009).
Incidence of additional coronary angioplasty or bypass
surgery. The incidence of additional angioplasty or bypass
surgery for all patients is shown in Figure 8. The incidence is
considerably higher in the angioplasty group patients and
higher in both groups than for either angioplasty or bypass
surgery as end points alone. Few surviving patients in the
angioplasty group will be free of additional revascularization
by 7 or 8 years. The results in the insulin-requiring subgroup
were similar (data not shown). Freedom from the events of
death, myocardial infarction, additional angioplasty or bypass
surgery is shown in Figure 9. Initially, there was a much higher
incidence in the angioplasty group, and almost all angioplasty
group patients ultimately had a fatal or nonfatal event. How-
ever, the bypass surgery group patients continued to have a high
incidence of events over the full 10-year period. The results in the
insulin-requiring subgroup were similar (data not shown).
Figure 4. Survival, corrected for baseline differences, in
insulin-requiring patients.
Figure 5. Freedom from (FF) myocardial infarction (MI) in
all diabetic patients treated with coronary bypass surgery or
coronary angioplasty.
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Discussion
Review of results. Perhaps the most important finding of the
present study was that the long-term incidence of both fatal and
nonfatal events was high, emphasizing the palliative nature of
coronary revascularization. This finding limits the importance
of differences between the procedures. Although angioplasty
group patients were not as sick as the bypass surgery group
patients, and complete revascularization was achieved much
more often with bypass surgery, there was no difference in
survival, either for the group as a whole or for the insulin-
requiring subset. An interesting finding was that after account-
ing for baseline differences, there was still no difference
between the groups overall, but there was higher mortality in
the angioplasty group patients in the insulin-requiring subset.
Data on nonfatal events revealed a high incidence of additional
revascularization procedures, especially in the angioplasty
group patients. Because there may be more uncertainty con-
cerning therapy in patients with two-vessel disease, this group
Figure 6. Freedom from (FF) additional bypass surgery
(CABG) in all diabetic patients treated with coronary bypass
surgery or coronary angioplasty.
Figure 7. Freedom from (FF) additional coronary angio-
plasty (PTCA) in all diabetic patients treated with coronary
bypass surgery or coronary angioplasty.
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was considered separately. Patients with two-vessel disease had
a fatal and nonfatal event rate similar to the total population
for both types of therapy.
Previous descriptive series. Diabetes has been shown to be
a risk factor for increased long-term mortality events in
multiple studies, both after coronary angioplasty (4,5,17,17)
and bypass surgery (7,19,20). In the study by Stein et al. (4) the
5-year survival rate was 89% in diabetic versus 93% in nondi-
abetic patients, and freedom from infarction was 81% in
diabetic versus 89% in nondiabetic patients. Bypass surgery
and repeat coronary angioplasty were required more often in
diabetic patients. Survival free of infarction or repeat revascu-
larization was only 36% in diabetic versus 53% in nondiabetic
patients, with a marked attrition in the first year after angio-
plasty, which corresponds to the period when restenosis is most
common. In the study by Kip et al. (5), the 9-year survival rate
was 64% in diabetic and 82% in nondiabetic patients. Freedom
from infarction or repeat procedures was also lower in diabetic
patients. In addition, diabetes has been shown to be a risk
factor for restenosis (21–28). In a previous study (7) of 10,291
Figure 8. Freedom from (FF) either additional bypass sur-
gery (CABG) or angioplasty (PTCA) in all diabetic patients
treated with coronary bypass surgery or angioplasty.
Figure 9. Freedom from (FF) death, myocardial infarction,
additional bypass surgery or coronary angioplasty in all
diabetic patients treated with coronary bypass surgery or
coronary angioplasty.
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patients without and 2,372 with diabetes undergoing bypass
surgery, the in-hospital mortality rate was 1.8% without dia-
betes and 4.2% with diabetes. In that study, diabetic patients
were shown to have a lower 5- (74% vs. 87%) and 10-year
(50% vs 72%) survival rate than nondiabetic patients.
Randomized trial data. Although the Emory Angioplasty
Versus Surgery (EAST) study (29) showed no survival differ-
ence between bypass surgery and coronary angioplasty in a
small number of treated diabetic patients, recent evidence
from the BARI (8) and CABRI (9) studies have suggested that
diabetic patients treated with insulin or oral agents are at
increased risk compared with all other patients and that the
risk is higher in the treated diabetic patients in the angioplasty
arm. Thus, in the BARI study at 5 years, the survival rate was
65.5% in the angioplasty group and 80.6% in the bypass
surgery group, which compares with 71.6% in the angioplasty
group and 70.1% in the bypass surgery group in the present
study, or 68% and 75% after accounting for baseline differ-
ences. Thus, although the results are not as divergent between
treatment arms in the present study as in the BARI study, they
are similar in direction and in overall mortality.
Limitations and conclusions. The major limitation of data
concerning choice of therapy from an observational database is
that selection bias cannot be overcome, because the variables
that account for selection of therapy may not be included or
may not be adequately accounted for. However, randomized
data can be limited in generalizability. Thus, observations in a
randomized trial may only be true for patients within the trial.
Thus, from a medical decision-making point of view it is
optimum if the randomized data and observational data are
similar. The results of randomized trial data as well as the
present study raise concerns about performing angioplasty in
treated, and especially in insulin-requiring, diabetic patients
with multivessel coronary artery disease. However, a definitive
answer that only bypass surgery should be performed in such
patients would probably overstate the issue. This is because of
concern about generalizing the BARI results to broader pop-
ulations, selection bias in nonrandomized studies and the wide
95% confidence interval surrounding the odds ratio for angio-
plasty versus bypass surgery (Fig 3). However, the data are
directionally similar in the BARI study and the present study.
Furthermore, the high incidence of nonfatal events in the
angioplasty group is also disturbing.
It is worth pointing out that decision making has been away
from coronary angioplasty and toward bypass surgery in the
majority of these patients in any case. The 279 patients with
insulin-requiring diabetes and multivessel disease who under-
went angioplasty represent 1.5% of 18,591 patients undergoing
angioplasty at Emory during this period. Furthermore, in the
insulin-requiring diabetic patients, 31% underwent angioplasty
as opposed to 35% of the noninsulin-requiring diabetic pa-
tients (p 5 0.048). Finally, of patients with insulin-requiring
diabetes and three-vessel disease, only 73 (15%) of 411 under-
went angioplasty, 5 of whom were enrolled in the EAST trial
(29). Thus, medical decision making has already directed most
of the most seriously ill patients with insulin-requiring diabetes
away from angioplasty toward bypass surgery. Although the
data presented in the present study and results from the
randomized trials may not be sufficient to make a definitive
recommendation about the choice of revascularization in all
treated diabetic patients with multivessel coronary disease, the
place of angioplasty in these high risk patients is uncertain.
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